AI Engines For more Details: Perplexity Kagi Labs You
Subarachnoid Hemorrhage (SAH): Nimodipine is widely used in the treatment of subarachnoid hemorrhage, which is a type of stroke caused by bleeding into the space surrounding the brain. It works by blocking calcium channels in blood vessels, particularly in the brain, thereby improving blood flow and reducing the risk of vasospasm, a potentially serious complication that can occur after SAH. Vasospasm involves the narrowing of blood vessels in the brain, which can lead to reduced blood flow, ischemia, and further neurological damage. Nimodipine helps prevent or minimize vasospasm and its associated complications, such as delayed cerebral ischemia (DCI), improving neurological outcomes and reducing mortality in patients with SAH.
Cerebral Ischemia: Nimodipine's vasodilatory effects also make it potentially useful in the treatment of cerebral ischemia, a condition characterized by inadequate blood supply to the brain, leading to tissue damage and neurological deficits. By dilating cerebral blood vessels, nimodipine can improve cerebral perfusion and oxygenation, potentially reducing the severity of ischemic injury and improving outcomes in patients with conditions such as ischemic stroke.
Other Neurological Disorders: While nimodipine's primary indication is SAH, there is ongoing research into its potential therapeutic effects in other neurological disorders, such as traumatic brain injury, Alzheimer's disease, and vascular dementia. However, its efficacy in these conditions remains under investigation, and further clinical studies are needed to determine its role in their management.
Side Effects: Like all medications, nimodipine can cause side effects, although they are generally mild and transient. Common side effects may include hypotension (low blood pressure), headache, flushing, dizziness, nausea, and gastrointestinal disturbances. In some cases, nimodipine may also cause allergic reactions or more severe adverse effects such as reflex tachycardia or peripheral edema.
Administration Route: Nimodipine is typically administered orally in the form of capsules or liquid. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional to ensure optimal therapeutic benefits and minimize the risk of adverse effects.
Drug Interactions: Nimodipine may interact with other medications, particularly those that affect blood pressure or cardiovascular function. It is essential to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential drug interactions.
Monitoring: Patients receiving nimodipine therapy may require regular monitoring of blood pressure and clinical status to assess treatment response and detect any adverse effects promptly.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.7 | 0.7 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4.9 | 0.9 | 4.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.9 | 2 | 0.45 |
| Allergies | 7.2 | 4.2 | 0.71 |
| Allergy to milk products | 1.6 | 1.6 | 0 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.5 | 7.8 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 0.6 | 4.33 |
| Ankylosing spondylitis | 4.4 | 0.9 | 3.89 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.3 | 0.3 | 3.33 |
| Asthma | 5.2 | 2.4 | 1.17 |
| Atherosclerosis | 2 | 2.3 | -0.15 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 9.6 | 9.4 | 0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.3 | 1.67 |
| Cancer (General) | 0.6 | 2.2 | -2.67 |
| Carcinoma | 4.3 | 2.6 | 0.65 |
| Celiac Disease | 2.6 | 3.5 | -0.35 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 5.1 | 7.2 | -0.41 |
| Chronic Kidney Disease | 4.6 | 3 | 0.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.7 | 0.18 |
| Chronic Urticaria (Hives) | 1.6 | 1.2 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 8.4 | 2.7 | 2.11 |
| Constipation | 1.8 | 1.3 | 0.38 |
| Coronary artery disease | 2 | 3.1 | -0.55 |
| COVID-19 | 9.6 | 12.6 | -0.31 |
| Crohn's Disease | 7.8 | 5.5 | 0.42 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.7 | 1.4 | 0.93 |
| Denture Wearers Oral Shifts | 1.6 | 1.6 | |
| Depression | 11 | 9.4 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 3.2 | -1.29 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.1 | 1.8 | 0.72 |
| erectile dysfunction | 1.6 | 0.3 | 4.33 |
| Fibromyalgia | 3.5 | 3.1 | 0.13 |
| Functional constipation / chronic idiopathic constipation | 5.5 | 4.8 | 0.15 |
| gallstone disease (gsd) | 3.4 | 0.9 | 2.78 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 1.2 | 0 |
| Generalized anxiety disorder | 2.2 | 2.2 | 0 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.2 | 1.1 | 1 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.4 | -0.56 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.7 | 1.8 | 1.06 |
| Heart Failure | 3.7 | 2 | 0.85 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.1 | 6 |
| hyperglycemia | 2.7 | 1.2 | 1.25 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.8 | 5.7 | -0.19 |
| Hypothyroidism | 0 | 1 | 0 |
| Hypoxia | 3 | 0.8 | 2.75 |
| IgA nephropathy (IgAN) | 1.6 | 4.7 | -1.94 |
| Inflammatory Bowel Disease | 8.2 | 9.5 | -0.16 |
| Insomnia | 2.9 | 2.5 | 0.16 |
| Intelligence | 1.7 | 0.5 | 2.4 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 7.3 | 5.1 | 0.43 |
| ischemic stroke | 2.6 | 1.7 | 0.53 |
| Liver Cirrhosis | 8.1 | 4.3 | 0.88 |
| Long COVID | 6.8 | 7.9 | -0.16 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.1 | 0.36 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 1.1 | 2.4 | -1.18 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.8 | 0.6 | 2 |
| Metabolic Syndrome | 7.6 | 7.7 | -0.01 |
| Mood Disorders | 10.9 | 7.6 | 0.43 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 6.2 | 6.5 | -0.05 |
| Multiple system atrophy (MSA) | 0.9 | 0.7 | 0.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 2.8 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.6 | 4.7 | 0.19 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 11.1 | 7.7 | 0.44 |
| obsessive-compulsive disorder | 6.3 | 3.7 | 0.7 |
| Osteoarthritis | 2.7 | 1.2 | 1.25 |
| Osteoporosis | 3 | 1.6 | 0.88 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 9.3 | 7 | 0.33 |
| Polycystic ovary syndrome | 6.7 | 3.3 | 1.03 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 2.3 | 2.6 | -0.13 |
| Psoriasis | 3.5 | 3.4 | 0.03 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.6 | 4.4 | 0.73 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.1 | 3.1 | 1.29 |
| scoliosis | 0.5 | 1.1 | -1.2 |
| Sjögren syndrome | 3.1 | 3.3 | -0.06 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.3 | 4.33 |
| Stress / posttraumatic stress disorder | 2.6 | 2.4 | 0.08 |
| Systemic Lupus Erythematosus | 4 | 2 | 1 |
| Tic Disorder | 1.2 | 1.7 | -0.42 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 5.4 | 3.7 | 0.46 |
| Type 2 Diabetes | 8.5 | 7.5 | 0.13 |
| Ulcerative colitis | 5.8 | 7.3 | -0.26 |
| Unhealthy Ageing | 5.1 | 2.5 | 1.04 |
| Vitiligo | 2.5 | 1.6 | 0.56 |
